Bifogade filer
Interim Report Q2 2024
Kurs
-7,71%
Likviditet
13,3 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2026-02-05 | 07:30 | Bokslutskommuniké 2025 |
| 2025-11-06 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-18 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-06 | - | Årsstämma |
| 2025-04-29 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | 07:30 | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-19 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-06 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
| 2024-05-03 | - | Årsstämma |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-07 | - | Bokslutskommuniké 2023 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-20 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-08 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
| 2023-05-05 | - | Årsstämma |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-07 | - | Bokslutskommuniké 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-20 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning CEVI 2.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-04 | - | Bokslutskommuniké 2021 |
| 2021-10-22 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-30 | - | X-dag ordinarie utdelning CEVI 0.75 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-04 | - | Bokslutskommuniké 2020 |
| 2020-10-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-17 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
| 2020-06-16 | - | Årsstämma |
| 2020-04-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-05 | - | Bokslutskommuniké 2019 |
| 2019-10-23 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-07 | - | Bokslutskommuniké 2018 |
| 2018-10-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-07 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
| 2018-05-04 | - | Årsstämma |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-09 | - | Bokslutskommuniké 2017 |
| 2017-10-25 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-08 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
| 2017-05-05 | - | Årsstämma |
| 2017-05-04 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-07 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-06 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
| 2016-05-04 | - | Årsstämma |
| 2016-05-03 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-12 | - | Bokslutskommuniké 2015 |
| 2015-11-09 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-17 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | - | X-dag ordinarie utdelning CEVI 1.00 SEK |
| 2015-05-06 | - | Årsstämma |
| 2015-05-05 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-12 | - | Bokslutskommuniké 2014 |
| 2014-11-05 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-18 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-08 | - | X-dag ordinarie utdelning CEVI 0.50 SEK |
| 2014-05-07 | - | Årsstämma |
| 2014-05-06 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-13 | - | Bokslutskommuniké 2013 |
| 2013-10-24 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-17 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-25 | - | X-dag ordinarie utdelning CEVI 0.40 SEK |
| 2013-04-24 | - | Årsstämma |
| 2013-04-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-14 | - | Bokslutskommuniké 2012 |
| 2012-10-26 | - | Kvartalsrapport 2012-Q3 |
| 2012-07-18 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-24 | - | Kapitalmarknadsdag 2012 |
| 2012-05-03 | - | X-dag ordinarie utdelning CEVI 0.40 SEK |
| 2012-05-02 | - | Årsstämma |
| 2012-04-25 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-14 | - | Bokslutskommuniké 2011 |
| 2011-10-25 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-15 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-27 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
| 2011-04-26 | - | Årsstämma |
| 2011-04-20 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-15 | - | Bokslutskommuniké 2010 |
| 2010-10-27 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-16 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-30 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
| 2010-04-29 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-12 | - | Bokslutskommuniké 2009 |
| 2009-10-23 | - | Kvartalsrapport 2009-Q3 |
| 2009-07-15 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-27 | - | Årsstämma |
| 2009-04-27 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Organic sales growth:
Q2, 2024: 10% (-15)
EBITDA margin:
Q2, 2024: 32% (33)
January 1 – June 30, 2024
- Net sales increased by 11% (-8) to SEK 188 m (170).
- Sales increased organically by 10% (-15), currency effect 1% (7).
- EBITDA increased to SEK 60 m (56).
- EBITDA margin amounted to 32% (33).
- Profit before tax increased to SEK 48 m (44).
- Earnings per share before and after dilution increased to SEK 1.62 (1.46).
- Cash flow from operating activities increased to SEK 40 m (28).
Contact
Adele Horn
Corporate Communications & Investor Relations Manager
Tel: + 46 46 460 26 04
www.cellavision.com
adele.horn@cellavision.com
About Us
CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 12 local market support organizations covering more than 40 countries. In 2023, sales were SEK 677 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com
This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-19 07:20 CEST.